Cancelo MJ - Search Results

1

Vulvovaginal atrophy in the CRETA study: the healthcare professionals' perception.

Cancelo MJ, Sánchez Borrego R, Palacios S, Baquedano L, Corbacho Garza T, Fernández Aller N, García Ferreiro C, Quijano Martín JJ, González Calvo AJ. Cancelo MJ, et al. Gynecol Endocrinol. 2023 Dec;39(1):2264405. doi: 10.1080/09513590.2023.2264405. Epub 2023 Oct 9. Gynecol Endocrinol. 2023. PMID: 37811796 Free article.

2

Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.

Palacios S, Castelo-Branco C, Cancelo MJ, Vázquez F. Palacios S, et al. Among authors: cancelo mj. Maturitas. 2005 Feb 14;50(2):98-104. doi: 10.1016/j.maturitas.2004.04.007. Maturitas. 2005. PMID: 15653006 Clinical Trial.

3

Relevance of the results of the Women's Health Initiative on the prescription of hormone therapy in Spain.

Neyro JL, Cancelo MJ, Quereda F, Palacios S; NAMS Group of the AEEM. Neyro JL, et al. Among authors: cancelo mj. Climacteric. 2005 Mar;8(1):36-48. doi: 10.1080/13697130500062662. Climacteric. 2005. PMID: 15804730

4

Women's perception of the efficacy of a soy extract with probiotic: the M3 study.

Palacios S, Rojo IA, Cancelo MJ, Neyro JL, Castelo-Branco C. Palacios S, et al. Among authors: cancelo mj. Gynecol Endocrinol. 2008 Apr;24(4):178-83. doi: 10.1080/09513590801954687. Gynecol Endocrinol. 2008. PMID: 18382902 Clinical Trial.

5

Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy.

Palacios S, Cancelo MJ. Palacios S, et al. Among authors: cancelo mj. Int J Womens Health. 2016 Oct 26;8:617-626. doi: 10.2147/IJWH.S110035. eCollection 2016. Int J Womens Health. 2016. PMID: 27822125 Free PMC article. Review.

6

Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions.

Palacios S, Cancelo MJ, Castelo Branco C, Llaneza P, Molero F, Borrego RS. Palacios S, et al. Among authors: cancelo mj. Climacteric. 2017 Feb;20(1):55-61. doi: 10.1080/13697137.2016.1262840. Epub 2017 Jan 2. Climacteric. 2017. PMID: 28042734

7

Is pH a vaginal health marker? Phemale Study.

Palacios S, González SP, Cancelo MJ. Palacios S, et al. Among authors: cancelo mj. Minerva Ginecol. 2018 Apr;70(2):138-143. doi: 10.23736/S0026-4784.17.04102-8. Epub 2017 Sep 5. Minerva Ginecol. 2018. PMID: 28891279

8

Impact of vulvovaginal atrophy therapies on postmenopausal women's quality of life in the CRETA study measured by the Cervantes scale.

Palacios S, Sánchez-Borrego R, Suárez Álvarez B, Lugo Salcedo F, González Calvo AJ, Quijano Martín JJ, Cancelo MJ, Fasero M. Palacios S, et al. Among authors: cancelo mj. Maturitas. 2023 Jun;172:46-51. doi: 10.1016/j.maturitas.2023.03.007. Epub 2023 Mar 30. Maturitas. 2023. PMID: 37099983 Free article.

9

Sequential management of postmenopausal health and osteoporosis: An update.

Calaf-Alsina J, Cano A, Guañabens N, Palacios S, Cancelo MJ, Castelo-Branco C, Larrainzar-Garijo R, Neyro JL, Nogues X, Diez-Perez A. Calaf-Alsina J, et al. Among authors: cancelo mj. Maturitas. 2023 Nov;177:107846. doi: 10.1016/j.maturitas.2023.107846. Epub 2023 Sep 13. Maturitas. 2023. PMID: 37738717 Free article. Review.

10

Eligibility criteria for using menopausal hormone therapy in breast cancer survivors: a safety report based on a systematic review and meta-analysis.

Coronado PJ, Gómez A, Iglesias E, Fasero M, Baquedano L, Sánchez S, Ramírez-Polo I, de la Viuda E, Otero B, Llaneza P, Mendoza N, Lubián DM; HMT Eligibility Criteria Group. Coronado PJ, et al. Menopause. 2024 Mar 1;31(3):234-242. doi: 10.1097/GME.0000000000002317. Menopause. 2024. PMID: 38385734

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page